logo
Plus   Neg
Share
Email

Xbrane And STADA Enter Into Co-development Agreement For Xlucane

Xbrane Biopharma AB and STADA Arzneimittel AG have entered into a co-development agreement for Xlucane, a Lucentis (ranibizumab) biosimilar.

The collaboration between Xbrane and STADA is based on a co-development agreement, meaning that the companies will equally contribute to development expenses and share profits from commercialization in a 50/50 split.

STADA will make an upfront payment to Xbrane of EUR 7.5 million. In close consultation and agreement with STADA, Xbrane will be responsible for the development of the product until completion of the marketing authorization applications to EMA (European Medicines Agency) and FDA (US Food and Drug Administration), as well as for supply of the finished pharmaceutical product.

STADA said it will hold the marketing authorizations and will be responsible for sales and marketing of the product across all territories included in the agreement. The co-development agreement covers Europe, the US and a variety of MENA and APAC markets.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Following the sell-off seen in the previous session, stocks showed another significant move to the downside during trading on Tuesday. With the continued drop, the tech-heavy Nasdaq fell to its lowest closing level in over seven months. A federal judge in San Francisco has temporarily blocked President Donald Trump's plan to restrict asylum claims by illegal immigrants. In a ruling issued late Monday, U.S. District Court Judge Jon Tigar accused the Trump administration of trying to rewrite immigration laws. Bank of England Governor Mark Carney welcomed the draft Brexit deal and the transition arrangement that the British Prime Minister Theresa May struck with the European Union last week, but warned that the risks of a "no-deal, no-transition" scenario remained very high. Speaking at a Treasury Select Committee hearing, Carney said, "We welcome the transition arrangements in the withdrawal deal."
Follow RTT